Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Equity Average (2019 - 2025)

Historic Equity Average for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $705.2 million.

  • Keros Therapeutics' Equity Average rose 4787.03% to $705.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $705.2 million, marking a year-over-year increase of 4787.03%. This contributed to the annual value of $451.9 million for FY2024, which is 4824.68% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Equity Average is $705.2 million, which was up 4787.03% from $717.8 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Equity Average ranged from a high of $717.8 million in Q2 2025 and a low of $217.4 million during Q2 2022
  • Moreover, its 5-year median value for Equity Average was $314.0 million (2023), whereas its average is $374.0 million.
  • In the last 5 years, Keros Therapeutics' Equity Average soared by 125111.37% in 2021 and then plummeted by 1019.07% in 2022.
  • Keros Therapeutics' Equity Average (Quarter) stood at $230.8 million in 2021, then increased by 12.3% to $259.2 million in 2022, then grew by 21.14% to $314.0 million in 2023, then soared by 75.84% to $552.2 million in 2024, then grew by 27.7% to $705.2 million in 2025.
  • Its last three reported values are $705.2 million in Q3 2025, $717.8 million for Q2 2025, and $650.2 million during Q1 2025.